Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Exelixis Shares Got Decimated: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotech Exelixis (Nasdaq: EXEL  ) are being dumped like the plague today, down by as much as a gut-wrenching 41% so far, after the company failed to reach an agreement with regulators over special rules with its phase 3 trial.

So what: The drug in question, cabozantinib, is an experimental prostate cancer drug, and the company plans on measuring its effectiveness by pain reduction in the trial. Exelixis has decided to proceed with the study since it is in the company's best interest, despite lacking regulators' blessings.

Now what: Exelixis is looking to initiate the trial by year's end, and a different trial to measure overall survival in the first half of 2012. The company indicated that leading investigators and consultants advised it to proceed, since it would be in the best interests of patients and Exelixis to initiate the trial as soon as possible. It's a risky move to proceed without getting regulators to sign off on the trial, but biotech investors should be no strangers to risk.

Interested in more info on Exelixis? Add it to your watchlist by clicking here.

Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 01, 2011, at 5:32 PM, CMFMLove wrote:

    Etymologically, "decimated" means that 1 in 10 gets killed. The word derives from the Roman practice of killing one of every ten soldiers from units that fled in battle. Today was much worse for Exelisis. Even so, Exelisis owners are used to this sort of thing. I still think it will all work out.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1581460, ~/Articles/ArticleHandler.aspx, 10/26/2016 7:41:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
EXEL $11.30 Up +0.01 +0.09%
Exelixis CAPS Rating: ****